Synmosa Biopharma (4114) - Total Assets
Based on the latest financial reports, Synmosa Biopharma (4114) holds total assets worth NT$13.99 Billion TWD (≈ $440.61 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Synmosa Biopharma to assess how comfortably operating cash covers total debt obligations.
Synmosa Biopharma - Total Assets Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Synmosa Biopharma for net asset value and shareholders' equity analysis.
Synmosa Biopharma - Asset Composition Analysis
Current Asset Composition (December 2025)
Synmosa Biopharma's total assets of NT$13.99 Billion consist of 47.7% current assets and 52.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 13.5% |
| Accounts Receivable | NT$1.29 Billion | 9.3% |
| Inventory | NT$2.19 Billion | 15.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$383.90 Million | 2.8% |
| Goodwill | NT$50.26 Million | 0.4% |
Asset Composition Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4114 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synmosa Biopharma's current assets represent 47.7% of total assets in 2025, an increase from 25.9% in 2015.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, up from 5.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 15.7% of total assets.
Synmosa Biopharma Competitors by Total Assets
Key competitors of Synmosa Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Alkermes plc
F:8AK
|
Germany | €4.26 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Synmosa Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.95 | 2.42 | 1.76 |
| Quick Ratio | 1.98 | 1.60 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$4.41 Billion | NT$2.94 Billion | NT$1.29 Billion |
Synmosa Biopharma - Advanced Valuation Insights
This section examines the relationship between Synmosa Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 13.7% |
| Total Assets | NT$13.99 Billion |
| Market Capitalization | $460.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Synmosa Biopharma's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Synmosa Biopharma's assets grew by 13.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Synmosa Biopharma (2015–2025)
The table below shows the annual total assets of Synmosa Biopharma from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$13.99 Billion ≈ $440.61 Million |
+13.66% |
| 2024-12-31 | NT$12.30 Billion ≈ $387.65 Million |
+4.91% |
| 2023-12-31 | NT$11.73 Billion ≈ $369.51 Million |
+4.70% |
| 2022-12-31 | NT$11.20 Billion ≈ $352.94 Million |
+8.59% |
| 2021-12-31 | NT$10.32 Billion ≈ $325.04 Million |
-0.58% |
| 2020-12-31 | NT$10.38 Billion ≈ $326.95 Million |
+18.87% |
| 2019-12-31 | NT$8.73 Billion ≈ $275.04 Million |
+15.71% |
| 2018-12-31 | NT$7.54 Billion ≈ $237.70 Million |
+0.55% |
| 2017-12-31 | NT$7.50 Billion ≈ $236.41 Million |
+10.52% |
| 2016-12-31 | NT$6.79 Billion ≈ $213.90 Million |
+47.83% |
| 2015-12-31 | NT$4.59 Billion ≈ $144.70 Million |
-- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more